OSLO, Norway--(BUSINESS WIRE)--PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today the main results of the completed Phase I/II study of the new component Amphinex® in the combination productPC-A11, where Amphinex is used in combination with the cytotoxic agent bleomycin. The primary objective of this dose escalation study is to assess the maximum tolerated dose of the new component Amphinex®. Secondary objectives include determination of the antitumour effect of the PC-A11 treatment, as well as pharmacokinetics of the Amphinex® component.